Cargando…

Precision Medicine in Graves’ Disease: CD40 Gene Variants Predict Clinical Response to an Anti-CD40 Monoclonal Antibody

BACKGROUND: CD40, a key co-stimulatory molecule expressed on antigen-presenting cells, is genetically associated with a number of autoimmune diseases including Graves’ disease (GD). Therefore, recent therapies targeting CD40 have been developed, including the anti-CD40 monoclonal antibody Iscalimab....

Descripción completa

Detalles Bibliográficos
Autores principales:	Faustino, Larissa C., Kahaly, George J., Frommer, Lara, Concepcion, Erlinda, Stefan-Lifshitz, Mihaela, Tomer, Yaron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212124/ https://www.ncbi.nlm.nih.gov/pubmed/34149627 http://dx.doi.org/10.3389/fendo.2021.691781

Ejemplares similares

OR19-6 A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, Successfully Treats Graves’ Hyperthyroidism
por: Kahaly, George, et al.
Publicado: (2019)

Compelling Evidence Linking CD40 Gene With Graves’ Disease in the Chinese Han Population
por: Jiang, He, et al.
Publicado: (2021)

Dissecting the Genetic Susceptibility to Graves’ Disease in a Cohort of Patients of Italian Origin
por: Lombardi, Angela, et al.
Publicado: (2016)

Type 1 Diabetes and Autoimmune Thyroid Disease—The Genetic Link
por: Frommer, Lara, et al.
Publicado: (2021)

CD40–CD40L in Neurological Disease
por: Ots, Heather D., et al.
Publicado: (2022)

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves’ Orbitopathy
por: George, Augustine, et al.
Publicado: (2021)

Soluble CD40 Ligand Levels in Children with Newly Diagnosed Graves’ Disease
por: Metwalley, Kotb Abbass, et al.
Publicado: (2020)

Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease
por: Kahaly, George J, et al.
Publicado: (2019)

Adipocytes in their (CD)40s
por: Bertola, Adeline, et al.
Publicado: (2023)

CD40-CD40L Interaction in Immunity Against Protozoan Infections
por: Chamekh, Mustapha
Publicado: (2007)

The Role of CD40/CD40 Ligand Interactions in Bone Marrow Granulopoiesis
por: Mavroudi, Irene, et al.
Publicado: (2011)

CD40/CD40 LIGAND INTERACTIONS IN IMMUNE RESPONSES AND PULMONARY IMMUNITY
por: KAWABE, TSUTOMU, et al.
Publicado: (2011)

The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease
por: Bosmans, Laura A., et al.
Publicado: (2020)

Platelets as Key Factors in Inflammation: Focus on CD40L/CD40
por: Cognasse, Fabrice, et al.
Publicado: (2022)

Levels of human platelet-derived soluble CD40 ligand depend on haplotypes of CD40LG-CD40-ITGA2
por: Aloui, Chaker, et al.
Publicado: (2016)

Commentary: Brief report - Monoclonal antibodies illustrate the difficulties in measuring blocking TSH receptor antibodies
por: Olivo, Paul D., et al.
Publicado: (2022)

CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches
por: Argiriadi, Maria A., et al.
Publicado: (2019)

CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells
Publicado: (1990)

Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis
por: Teruel, María, et al.
Publicado: (2012)

The Contribution of CD40/CD40L Axis in Inflammatory Bowel Disease: An Update
por: Senhaji, Nezha, et al.
Publicado: (2015)

The CD40–CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
por: Aarts, Suzanne A. B. M., et al.
Publicado: (2017)

CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation
por: Elmetwali, Taha, et al.
Publicado: (2020)

Downregulation of CD40L–CD40 attenuates seizure susceptibility and severity of seizures
por: Pototskiy, Esther, et al.
Publicado: (2021)

CD40/CD40L expression and its prognostic value in cervical cancer
por: Grazia, G.A., et al.
Publicado: (2023)

Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
por: Richman, Lee P, et al.
Publicado: (2014)

CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy
por: Zhang, Juan, et al.
Publicado: (2022)

RNA aptamers with specific binding affinity to CD40 (CD40Apt) represents a promising antagonist of the CD40-CD40L signaling for thyroid-associated ophthalmopathy (TAO) treatment in mouse
por: Chen, Yizhi, et al.
Publicado: (2023)

Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an exploratory study
por: Lee, Hanna J., et al.
Publicado: (2023)

Agonistic CD40 Antibodies in Cancer Treatment
por: Djureinovic, Dijana, et al.
Publicado: (2021)

Disturbances of Modulating Molecules (FOXP3, CTLA-4/CD28/B7, and CD40/CD40L) mRNA Expressions in the Orbital Tissue from Patients with Severe Graves' Ophthalmopathy
por: Pawlowski, Przemyslaw, et al.
Publicado: (2015)

SAT-429 Systemic Safety Analysis of Mycophenolate in Graves’ Orbitopathy
por: Lee, Alan C H, et al.
Publicado: (2020)

CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40
Publicado: (1993)

Expression of CD40 and CD40L in Gastric Cancer Tissue and Its Clinical Significance
por: Li, Rui, et al.
Publicado: (2009)

Expression of CD40, CD40L and IgM production in patients with ataxia-telangiectasia
por: Pereira, Camila Teles Machado, et al.
Publicado: (2015)

The association of CD40 polymorphisms with CD40 serum levels and risk of systemic lupus erythematosus
por: Chen, Jian-Ming, et al.
Publicado: (2015)

Multiple effects of CD40–CD40L axis in immunity against infection and cancer
por: Ara, Anjuman, et al.
Publicado: (2018)

First trimester sCD40L levels associated with adverse neonatal outcomes in euthyroid pregnant women with positive TPOAb
por: Chen, Xinxin, et al.
Publicado: (2023)

A Critical Role for Cd40–Cd40 Ligand Interactions in Amplification of the Mucosal Cd8 T Cell Response
por: Lefrançois, Leo, et al.
Publicado: (1999)

The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities
por: Bjorck, Pia, et al.
Publicado: (2015)

Characterization of a Broadly Reactive Anti-CD40 Agonistic Monoclonal Antibody for Potential Use as an Adjuvant
por: Martin, Cameron, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lu4648su8a7fkg9gsd645hu4b3